A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany
A budget impact analysis of bezlotoxumab versus standard of care antibiotics only in patients at high risk of CDI recurrence from a hospital management perspective in Germany (BMC).
Antibiotika - Arzneimittel - Begleitforschung - Bezlotoxumab - Budgetverhandlung - Clostridium difficile - diagnosis related groups - DRG - Entgeltverhandlung - Fallkosten - Fallpauschalen - Hygiene - Kosten-Nutzen - Krankenhausbehandlung - Krankenhaushygiene - Leitlinien - Medikamente - monoklonale Antikörper - Nosokomiale Infektionen - Therapie - Therapiekosten - Verweildauer - Wiederaufnahmerate - Zusatzentgelt - URL